| 6.74 -0.1 (-1.46%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.45  |
1-year : | 9.87 |
| Resists | First : | 7.23 |
Second : | 8.45 |
| Pivot price | 5.68 |
|||
| Supports | First : | 5.1 |
Second : | 3.77 |
| MAs | MA(5) : | 6.5 |
MA(20) : | 5.3 |
| MA(100) : | 4.47 |
MA(250) : | 5.91 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 87.4 |
D(3) : | 88.9 |
| RSI | RSI(14): 75.6 |
|||
| 52-week | High : | 10.44 | Low : | 3.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AVXL ] has closed below upper band by 15.0%. Bollinger Bands are 168% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.25 - 7.29 | 7.29 - 7.32 |
| Low: | 6.64 - 6.67 | 6.67 - 6.7 |
| Close: | 6.69 - 6.74 | 6.74 - 6.79 |
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Fri, 26 Jul 2024
BNP Paribas Financial Markets Cuts Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Tue, 23 Jul 2024
Anavex Life Sciences (NASDAQ:AVXL) Shares Up 8.5% - MarketBeat
Tue, 23 Jul 2024
EF Hutton starts Anavex Life shares with buy rating, citing ANAVEX2-73's potential - Investing.com
Mon, 22 Jul 2024
Jupiter Asset Management Ltd. Buys 700,812 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Wed, 17 Jul 2024
Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth - Simply Wall St
Mon, 01 Jul 2024
Institutions own 38% of Anavex Life Sciences Corp. (NASDAQ:AVXL) shares but individual investors control 59% of the company - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 85 (M) |
| Shares Float | 82 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 37.9 (%) |
| Shares Short | 17,830 (K) |
| Shares Short P.Month | 21,820 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.61 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.7 % |
| Return on Equity (ttm) | -29 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -32 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -13.48 |
| PEG Ratio | 0 |
| Price to Book value | 4.18 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|